



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 11/02, 11/04, 11/10	A1	(11) International Publication Number: WO 97/04086 (43) International Publication Date: 6 February 1997 (06.02.97)
(21) International Application Number: PCT/EP96/03253 (22) International Filing Date: 16 July 1996 (16.07.96) (30) Priority Data: 95201979.2 18 July 1995 (18.07.95) EP (34) Countries for which the regional or international application was filed: NL et al. 60/001,477 18 July 1995 (18.07.95) US (71) Applicant (for all designated States except US): GIST-BROCADES B.V. [NL/NL]; Wateringseweg 1, P.O. Box 1, NL-2600 MA Delft (NL). (72) Inventor; and (75) Inventor/Applicant (for US only): DE VROOM, Erik [NL/NL]; De Meij van Streefkerkstraat 65, NL-2313 JM Leiden (NL). (74) Agents: VISSER-LUIRINK, Gesina et al.; Gist-Brocades N.V., Patents and Trademarks Dept., Wateringseweg 1, P.O. Box 1, NL-2600 MA Delft (NL).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: AN IMPROVED IMMOBILIZED PENICILLIN G ACYLASE (57) Abstract A new immobilized Penicillin G acylase with a surprisingly good performance has been provided for. By applying this new immobilized enzyme, β -lactam derivatives are prepared in high yield by enzymatic reaction of a parent amino β -lactam and a corresponding acylating agent.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

AN IMPROVED IMMOBILIZED PENICILLIN G ACYLASE

Technical field

5 The present invention relates to an improved immobilized Penicillin G acylase. Furthermore, the invention relates to the preparation of β -lactam antibiotics by enzymatic acylation of the parent amino β -lactam nucleus with the corresponding acylating agent using said immobilized enzyme.

10

Background and field of the invention

Enzymatic production of semisynthetic β -lactam antibiotics by acylation of the parent amino β -lactam moiety with an activated side chain acid derivative, such as an amide or an ester, is known from Dutch patent 158847, European patent applications 15 339751 and 473008, international patent applications WO 92/01061 and WO 93/12250, U.S. patent 3816253, and West German patent documents 2163792 and 2621618. The enzymes used in the art are 20 in most cases penicillin acylases obtained from *Escherichia coli* and are immobilized on various types of water-insoluble materials.

A drawback of the known enzymatic methods for the production of amoxycillin, ampicillin, cephadroxil, cephalixin, and cephradine is the high cost due to the selectivity of the immobilized enzyme. Said immobilized enzymes are capable of condensing activated side chain derivatives such as D(-)-phenylglycine amide (PGA), D(-)-phenylglycine methyl ester (PGM), D(-)-4-hydroxyphenylglycine amide (HPGA), D(-)-4-hydroxyphenylglycine methyl ester (HPGM), D(-)-2,5-dihydro-phenylglycine amide 30 (DPGA), and D(-)-2,5-dihydrophenylglycine methyl ester (DPGM) with amino β -lactams such as 6-amino-penicillanic acid (6-APA), 7-aminocephalosporanic acid (7-ACA), 7-amino-3-chloro-3-cephem-4-carboxylic acid (7-ACCA), 7-aminodesacetoxycephalosporanic acid (7-ADCA) and 7-amino-3-[(Z)-1-propenyl]-3-cephem-4-carboxylic acid. On the other hand, said immobilized enzymes will 35 also hydrolyse the activated side chain derivatives to worthless side chain acids. Also, the desired product hydrolyses to form

side chain acid and the parent amino β -lactam. A high ratio between synthesis and hydrolysis will lower the cost of activated side chain derivative.

From international patent application WO 93/12250 it is known that the ratio synthesis/hydrolysis for cephadroxil and cephalixin synthesis by *Escherichia coli* penicillin G acylase immobilized on Eupergit PCA is strongly dependent on the reaction conditions such as pH, concentration of reactants and temperature. The influence of the nature of the carrier material on the ratio synthesis/hydrolysis however, has not been taught.

From European patent 222462 it is known that amino groups can be introduced onto the carrier material by adding amino-polymers such as alginate amine, chitosan pectin, or polyethylene imine to the base gelling constituent of the carrier.

Surprisingly, it has been found that immobilization of *Escherichia coli* penicillin G acylase on a carrier consisting of a gelling agent and a polymer containing free amino groups gives an enzymatic catalyst with superior characteristics regarding the ratio synthesis/hydrolysis in the condensation reaction of activated side chain derivatives with amino β -lactams as compared to penicillin G acylases immobilized on other carriers.

Summary of the invention

The present invention provides Penicillin G acylase immobilized on a carrier comprising a gelling agent and a polymer containing free amino groups. Preferably the polymer is selected from the group consisting of alginate amine, chitosan, pectin, or polyethylene imine, and more preferably, the gelling agent is gelatin. Furthermore, by applying such an immobilized enzyme, an improved process for the preparation of a β -lactam derivative by an enzymatic reaction of the parent amino β -lactam with the corresponding acylating agent has been provided for.

Specific embodiments

Examples of β -lactam derivatives that may be produced by the process of this invention are amoxycillin, ampicillin, cephaclor, cephadroxil, cephprozil, cephalixin, and cephradine.

The acylase activity is independent of the substituents at the 3-position of the cephem compounds, e.g. hydrogen, halogen, (lower) alkoxy, methyl or methyl substituted with, for instance, (lower) alkoxy, (lower) alkanoyloxy, halogen, S-R₅ (where R₅ is (lower) alkyl, (lower) alkanoyl or an optionally substituted heterocyclic ring), N₊-R₆ (where R₆ is (lower) alkyl or an optionally substituted heterocyclic ring). By lower is meant 1-6 carbon atoms. A heterocyclic ring is defined as an unsaturated ring structure comprising at least one nitrogen, sulphur or oxygen atom.

The acylating agent may be a derivative of D(-)-phenylglycine, D(-)-4-hydroxyphenylglycine or D(-)-2,5-dihydro-phenylglycine such as a lower alkyl (methyl, ethyl, n-propyl or isopropyl) ester or an amide which is unsubstituted in the -CONH₂ group.

The corresponding amino β -lactam contains the same β -lactam nucleus as the β -lactam derivative prepared.

Generally, the reaction temperature of the process of this invention may vary between 0°C and 35°C. The optimal temperature depends on the substrates as has been mentioned in European patent application 473008 and has not been optimized in the comparative examples given. The suitable pH value depends on the nature and concentration of the substrates and is typically in the range of 5 to 9. For convenient operation control of pH is used. Suitable reaction times are from several minutes to several hours, in particular from 30 minutes to three hours.

In commercial processes involving the use of a catalyst e.g. an enzyme, the price of the catalyst is often an important parameter in the overall economy of the process. In such cases it is an advantage if the catalyst can be reused without loss of catalytic activity. To this end, it is advantageous to have the enzyme in a reusable form, for example, in immobilized or entrapped form. The following immobilized *Escherichia coli* penicillin acylases were investigated:

Type A: *Escherichia coli* penicillin acylase isolated as described in international patent application WO 92/12782. Immobilization was carried out as described in European patent application No. 222462.

- 4 -

Type B: Commercially available immobilized *Escherichia coli* penicillin G acylase from Recordati, Italy, as described in European patent application No. 473008.

Type C: Commercially available immobilized *Escherichia coli* penicillin G acylase from Boehringer Mannheim GmbH, Germany, known as Enzygel®.

Suitable enzyme concentrations may be from 0.1 U.ml⁻¹ to 100 U.ml⁻¹ (1 U = one unit of enzyme activity, see below).

Using the process according to this invention, extraordinary high synthesis/hydrolysis ratio's can be obtained.

Definitions and methods of analysis

Enzyme activity

As definition of penicillin G acylase activity the following is used: one unit (U) corresponds to the amount of enzyme that hydrolyses per minute 1 µmole penicillin G under standard conditions (100 g.l⁻¹ penicillin G potassium salt, 0.05 M potassium phosphate buffer, pH 8.0, 28°C).

HPLC analysis

Procedure A (amoxycillin)

Sample: 1:10 Dilution using 25% acetonitrile in 2 mM potassium phosphate buffer, pH 5

Column: Chromosphere C18, 5 µm (100 x 3.0 mm)

Solvent: 25% acetonitrile in 12 mM potassium phosphate buffer containing 0.2% sodium dodecyl sulphate, pH 2.6

Flow: 1 ml.min⁻¹

Detection: 214 nm

Retention: HPG (1.9 min); HPGA (3.1 min); 6-APA (3.4 min); amoxycillin (4.8 min); HPGM (7.3 min)

Procedure B (cephalexin)

Sample: 1:10 Dilution using 25% acetonitrile in 2 mM potassium phosphate buffer, pH 5

Column: Chromosphere C18, 5 µm (100 x 3.0 mm)

- 5 -

Solvent: 29% acetonitrile in 5 mM potassium phosphate buffer containing 0.2% sodium dodecyl sulphate, pH 3.1

Flow: 1 ml.min⁻¹

5 Detection: 214 nm

Retention: PG (0.8 min); 7-ADCA (1.3 min); PGA (3.7 min); cephalixin (6.2 min); PGM (7.8 min)

Procedure C (cephradine)

10 Sample: 1:150 Dilution using 3% 1-propanol in 50 mM phosphoric acid buffer, pH 3.0

Column: Nucleosil 120 3 C18 (250 x 4.0 mm)

Solvent: Eluent A: 50 mM phosphoric acid buffer, pH 3.0
Eluent B: 50% eluent A, 50% acetonitrile

15 Gradient: 0-5 min: 100% A; 5-10 min: from 100% A to 70% A; 10-18 min: 70% A; 18-18.1 min: from 70% A to 100% A.

Flow: 1 ml.min⁻¹

Detection: 220 nm

20 Retention: 7-ADCA (5.3 min); DPG (6.0 min); DPGA (9.1 min); DPGM (15.9 min); cephradine (18.5 min)

Procedure D (cephaclor)

25 Sample: 1:150 Dilution using 3% 1-propanol in 50 mM phosphoric acid buffer, pH 3.0

Column: Nucleosil 120 3 C18 (250 x 4.0 mm)

Solvent: Eluent A: 50 mM phosphoric acid buffer, pH 3.0
Eluent B: 50% eluent A, 50% acetonitrile

30 Gradient: 0-5 min: 100% A; 5-10 min: from 100% A to 70% A; 10-18 min: 70% A; 18-18.1 min: from 70% A to 100% A.

Flow: 1 ml.min⁻¹

Detection: 220 nm

35 Retention: 7-ACCA (3.2 min); PG (3.8 min); PGA (5.6 min); cephaclor (14.9 min)

- 6 -

Procedure E (ampicillin)

Sample: 1:200 Dilution using 33% acetonitrile in 3.4 mM potassium phosphate buffer, pH 6.9

Column: Chromosphere C18, 5 μ m (100 x 3.0 mm)

5 Solvent: 30% Acetonitrile in 5 mM potassium phosphate buffer containing 0.1% sodium dodecyl sulphate, pH 3.0

Flow: 1 ml.min⁻¹

Detection: 214 nm

10 Retention: PG (1.0 min); 6-APA (1.3 min); PGA (2.6 min); ampicillin (4.5 min); PGM (5.8 min)

Example 1

Synthesis of amoxycillin from 6-APA and HPGA using immobilized

15 *Escherichia coli* penicillin G acylase

To an aqueous solution (50 ml) containing 10 mM HPGA and 30 mM 6-APA is added 50 U of immobilized *Escherichia coli* penicillin G acylase at 21°C. The pH is adjusted to 6.0 and the reaction

20 is allowed to proceed under a nitrogen atmosphere with pH control using a 0.05 M solution of H₂SO₄ in water. At different time intervals (see tables below) samples are analyzed according to procedure A as described above. The molar ratio synthesis/hydrolysis (S/H) is calculated from the results thus obtained.

25

Time (min)	5	10	15	20	25	30	60	90	120
S/H-ratio	1.1	1.3	1.3	1.4	1.2	1.2	1.2	1.1	1.1

Table 1.1 Synthesis of amoxycillin using type A enzyme

30

Time (min)	18	60	90	110	150	180
S/H-ratio	0.6	0.7	0.7	0.7	0.6	0.5

Table 1.2 Synthesis of amoxycillin using type B enzyme

35

- 7 -

Time (min)	18	30	60	90	120
S/H-ratio	0.7	0.7	0.6	0.6	0.5

Table 1.3 Synthesis of amoxycillin using type C enzyme

5

Example 2

synthesis of amoxycillin from 6-APA and HPMG using immobilized *Escherichia coli* penicillin G acylase

10 To an aqueous solution (50 ml) containing 10 mM HPMG and 30 mM 6-APA is added 50 U of immobilized *Escherichia coli* penicillin G acylase at 21°C. The pH is adjusted to 6.0 and the reaction is allowed to proceed under a nitrogen atmosphere with pH control using a 0.05 M solution of H₂SO₄ in water. At different
15 time intervals (see tables below) samples are analyzed according to procedure A as described above. The molar ratio synthesis/hydrolysis (S/H) is calculated from the results thus obtained.

Time (min)	10	20	40	60
S/H-ratio	1.6	1.4	1.3	1.2

20

Table 2.1 Synthesis of amoxycillin using type A enzyme

Example 3

25 **synthesis of cephalexin from 7-ADCA and PGA using immobilized *Escherichia coli* penicillin G acylase**

To an aqueous solution (50 ml) containing 10 mM PGA and 30 mM 7-ADCA is added 50 U of immobilized *Escherichia coli* penicillin G
30 acylase at 21°C. The pH is adjusted to 7.0 and the reaction is allowed to proceed under a nitrogen atmosphere with pH control using a 0.05 M solution of H₂SO₄ in water. At different time intervals (see tables below) samples are analyzed according to procedure B as described above. The molar ratio synthesis/
35 hydrolysis (S/H) is calculated from the results thus obtained.

- 8 -

Time (min)	5	10	20	30
S/H-ratio	6.5	4.2	3.4	2.4

Table 3.1 Synthesis of cephalixin using type A enzyme

5

Time (min)	5	10	20	30
S/H-ratio	1.0	0.9	0.8	0.7

Table 3.2 Synthesis of cephalixin using type B enzyme

10

Example 4

Synthesis of cephradine from 7-ADCA and DPGM.HCl using immobilized *Escherichia coli* penicillin G acylase

15 To an aqueous solution (120 ml) containing 300 mM DPGM.HCl and 300 mM 7-ADCA is added immobilized *Escherichia coli* penicillin G acylase (units as given in tables). The pH is adjusted to the value given in the tables below and the reaction is allowed to proceed under a nitrogen atmosphere. At different time intervals
20 samples are analyzed according to procedure C as described above. The molar ratio synthesis/hydrolysis (S/H) is calculated from the results thus obtained.

Time (min)	26	62	75	106	120
Conversion (%)	40	63	63	58	54
S/H-ratio	12	4.0	2.9	2.0	1.9

25

Table 4.1 Synthesis of Cephradine at pH 7.5 using type A enzyme (12 U.ml⁻¹)

Time (min)	45	110	170	255
Conversion (%)	33	49	51	68
S/H-ratio	2.4	1.7	1.4	1.4

30

Table 4.2 Synthesis of Cephradine at pH 7.0 using type B enzyme (33 U.ml⁻¹)

35

Example 5**Synthesis of cephaclor from 7-ACCA and PGA using immobilized *Escherichia coli* penicillin G acylase**

To an aqueous solution (120 ml) containing PGA and 7-ACCA (concentrations and enzyme units as given in tables below) is added immobilized *Escherichia coli* penicillin G acylase. The pH is adjusted to 7.7 and the reaction proceeds with pH control using a 2.0 M solution of H₂SO₄ in water. At different time intervals (see tables below) samples are analyzed according to procedure D as described above. The molar ratio synthesis/hydrolysis (S/H) is calculated from the results thus obtained.

Time (min)	2	62	90
Conversion (%)	3	58	66
S/H-ratio	2.0	6.2	4.0

Table 5.1 Synthesis of cephaclor from PGA (0.5 M) and 7-ACCA (0.6M) using type A enzyme (9 U.ml⁻¹)

Time (min)	26	62	124	161	266
Conversion (%)	25	40	50	55	58
S/H-ratio	5.3	4.4	3.4	3.2	2.6

Table 5.2 Synthesis of cephaclor from PGA (0.6 M) and 7-ACCA (0.6 M) using type B enzyme (47 U.ml⁻¹)

Example 6**Synthesis of ampicillin from 6-APA and PGA using immobilized *Escherichia coli* penicillin G acylase**

To an aqueous solution (100 ml) containing 500 mM PGA and 300 mM 6-APA is added 100 U of immobilized *Escherichia coli* penicillin G acylase. The pH is adjusted to 7.5 and the reaction is allowed to proceed with pH control using a 6.0 M solution of HCl in water. At different time intervals samples are analyzed according to procedure E as described above. The conversion and

- 10 -

the molar ratio synthesis/hydrolysis (S/H) are calculated from the results thus obtained and given in the tables below.

Alginate amine (%)	0	1.0		2.0	3.0	
Conversion (%)	5	5	10	5	5	10
Time (min)	115	54	116	151	68	135
S/H-ratio	2.4	4.6	3.5	3.9	3.9	2.9

Table 6.1.1 Synthesis of Ampicillin using type A enzyme (as polymer alginate amine has been used)

Chitosan (%)	0	1.0		1.5		2.0		2.5		3.0	
Conversion (%)	5	5	10	5	10	5	10	5	10	5	10
Time (min)	115	34	73	22	51	26	62	30	57	26	52
S/H-ratio	2.4	2.5	2.6	2.4	2.4	2.1	2.1	2.5	2.0	3.4	3.4

Table 6.1.2 Synthesis of Ampicillin using type A enzyme (as polymer chitosan has been used)

Pectin (%)	0	2.0		3.0	
Conversion (%)	5	5	10	5	10
Time (min)	115	65	133	45	94
S/H-ratio	2.4	2.4	1.9	3.5	2.7

Table 6.1.3 Synthesis of Ampicillin using type A enzyme (as polymer pectin has been used)

Polyethylene imine (%)	0	1.0		2.0		3.0	
Conversion (%)	5	5	10	5	10	5	10
Time (min)	115	64	132	49	100	43	93
S/H-ratio	2.4	2.5	2.4	2.4	2.8	2.7	2.5

Table 6.1.4 Synthesis of Ampicillin using type A enzyme (as polymer polyethylene imine has been used)

- 11 -

Conversion (%)	5	10
Time (min)	43	92
S/H-ratio	2.3	2.4

5 *Table 6.2 Synthesis of Ampicillin using type B enzyme*

Conversion (%)	5	10
Time (min)	33	69
S/H-ratio	3.3	2.8

10

Table 6.3 Synthesis of Ampicillin using type C enzyme

Claims

1. Penicillin G acylase immobilized on a carrier comprising a gelling agent and a polymer containing free amino groups.
- 5 2. Penicillin G acylase according to claim 1, wherein the polymer is selected from the group consisting of alginate amine, chitosan, pectin, or polyethylene imine.
- 10 3. Penicillin G acylase according to claim 1 or 2, wherein the gelling agent is gelatin.
4. Penicillin G acylase according to any one of the preceding claims, wherein the enzyme used is from *Escherichia coli*, *Acetobacter*
15 *pasteurianum*, *Xanthomonas citrii*, *Kluyvera citrophila*, *Bacillus megaterium* or *Alcaligenes faecalis*.
5. Process for the preparation of a β -lactam derivative by an enzymatic reaction of the parent amino β -lactam with the
20 corresponding acylating agent applying an immobilized enzyme, characterized by the application of an enzyme as defined in any one of the claims 1-4.
6. A process according to claim 5, wherein the acylating
25 agent is selected from the group consisting of a derivative of D-phenylglycine, a derivative of D-p-hydroxyphenylglycine, and a derivative of D-2,5-dihydro-phenylglycine.
7. A process according to claim 5 or 6, wherein the result-
30 ing β -lactam derivative is selected from the group consisting of ampicillin, amoxycillin, cephaclor, cephalixin, cephadroxil, cephradine and cephprozil.
8. A process according to any one of the claims 5 - 7,
35 wherein the reaction is performed at a temperature in the range from about 0 to about 35°C, preferably above about 10°C.

- 13 -

9. A process according to any one of the claims 5 - 8, wherein the reaction is performed at a pH value in the range from above about 5 through about 9.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 96/03253

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N11/02 C12N11/04 C12N11/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,91 08287 (NOVONORDISK AS) 13 June 1991 see page 1, line 20 - page 5, line 8 ---	1-9
X	EP,A,0 297 912 (NOVO INDUSTRI AS) 4 January 1989 see page 2, line 47 - page 5, line 9 ---	1-9
X	GB,A,2 149 816 (KANSAI PAINT CO LTD) 19 June 1985 see page 1, line 6 - page 5, line 60 ---	1-9
Y	EP,A,0 122 681 (NEDERLANDSE ORG TOEGEPAST) 24 October 1984 see page 2, line 23 - line 35 see page 3, line 13 - line 22 see page 6 - page 7; example 1 --- -/--	1-9



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 November 1996

Date of mailing of the international search report

15. 11. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Sitch, W

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 96/03253

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP,A,0 222 462 (GIST BROCADES NV) 20 May 1987 cited in the application see the whole document ---	1-9
Y	WO,A,93 12250 (NOVONORDISK AS) 24 June 1993 cited in the application see the whole document ---	1-9
Y	WO,A,92 12782 (NOVONORDISK AS) 6 August 1992 cited in the application see page 6, line 2 - page 10, line 15 -----	1-9

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9108287	13-06-91	AT-T- 124720	15-07-95
		CA-A- 2066686	24-05-91
		DE-D- 69020741	10-08-95
		DE-T- 69020741	21-03-96
		EP-A- 0502035	09-09-92
		JP-T- 5501499	25-03-93
		US-A- 5279948	18-01-94

EP-A-0297912	04-01-89	DE-D- 3886280	27-01-94
		DE-T- 3886280	31-03-94
		WO-A- 8900195	12-01-89
		ES-T- 2061656	16-12-94
		JP-T- 1503677	14-12-89
		US-E- RE33441	13-11-90

GB-A-2149816	19-06-85	NONE	

EP-A-0122681	24-10-84	NL-A- 8301373	16-11-84
		JP-A- 59210891	29-11-84

EP-A-0222462	20-05-87	CA-A- 1337282	10-10-95
		CN-B- 1029987	11-10-95
		DE-A- 3687882	08-04-93
		ES-T- 2054614	16-08-94
		FI-B- 95044	31-08-95
		IE-B- 59798	06-04-94
		JP-T- 63501334	26-05-88
		KR-B- 9512803	21-10-95
		WO-A- 8703005	21-05-87
		US-A- 5405764	11-04-95
		US-A- 5137818	11-08-92
		US-A- 5314814	24-05-94

WO-A-9312250	24-06-93	AU-A- 3345193	19-07-93
		DE-T- 618979	18-05-95
		EP-A- 0618979	12-10-94
		ES-T- 2059285	16-11-94
		JP-T- 7502168	09-03-95
		SK-A- 63894	08-03-95
		US-A- 5470717	28-11-95

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9212782	06-08-92	AU-A- 1235992	27-08-92
		BG-A- 97981	25-04-94
		CA-A- 2101256	26-07-92
		CZ-A- 9301485	19-01-94
		EP-A- 0569462	18-11-93
		HU-A- 67012	30-01-95
		JP-T- 6504947	09-06-94
		SK-A- 78593	12-01-94

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.